410 related articles for article (PubMed ID: 34749770)
1. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
Guttmann-Gruber C; Piñón Hofbauer J; Tockner B; Reichl V; Klausegger A; Hofbauer P; Wolkersdorfer M; Tham KC; Lim SS; Common JE; Diem A; Ude-Schoder K; Hitzl W; Lagler F; Reichelt J; Bauer JW; Lang R; Laimer M
Orphanet J Rare Dis; 2021 Nov; 16(1):473. PubMed ID: 34749770
[TBL] [Abstract][Full Text] [Related]
2. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
[TBL] [Abstract][Full Text] [Related]
3. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series.
Kwon IJ; Kim SE; Kim SC; Lee SE
J Dermatol; 2024 Mar; 51(3):441-447. PubMed ID: 38115742
[TBL] [Abstract][Full Text] [Related]
6. ABCB5
Dieter K; Niebergall-Roth E; Daniele C; Fluhr S; Frank NY; Ganss C; Kiritsi D; McGrath JA; Tolar J; Frank MH; Kluth MA
Cytotherapy; 2023 Jul; 25(7):782-788. PubMed ID: 36868990
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
[TBL] [Abstract][Full Text] [Related]
8. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes.
Guttmann-Gruber C; Tockner B; Scharler C; Hüttner C; Common JE; Tay ASL; Denil SLIJ; Klausegger A; Trost A; Breitenbach J; Schnitzhofer P; Hofbauer P; Wolkersdorfer M; Diem A; Laimer M; Strunk D; Bauer JW; Reichelt J; Lang R; Piñón Hofbauer J
Sci Rep; 2018 Sep; 8(1):13430. PubMed ID: 30194425
[TBL] [Abstract][Full Text] [Related]
9. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study.
Kragballe K; Steijlen PM; Ibsen HH; van de Kerkhof PC; Esmann J; Sorensen LH; Axelsen MB
Arch Dermatol; 1995 May; 131(5):556-60. PubMed ID: 7741542
[TBL] [Abstract][Full Text] [Related]
11. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa.
Solis DC; Gorell ES; Teng C; Barriga M; Nazaroff J; Li S; Subica A; Lu Y; Marinkovich MP; Tang JY
Pediatr Dermatol; 2021 May; 38(3):704-706. PubMed ID: 33749033
[TBL] [Abstract][Full Text] [Related]
13. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
[TBL] [Abstract][Full Text] [Related]
14. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study.
Dubertret L; Wallach D; Souteyrand P; Perussel M; Kalis B; Meynadier J; Chevrant-Breton J; Beylot C; Bazex JA; Jurgensen HJ
J Am Acad Dermatol; 1992 Dec; 27(6 Pt 1):983-8. PubMed ID: 1479106
[TBL] [Abstract][Full Text] [Related]
16. Dystrophic epidermolysis bullosa pruriginosa is not associated with frequent FLG gene mutations.
Schumann H; Has C; Kohlhase J; Bruckner-Tuderman L
Br J Dermatol; 2008 Aug; 159(2):464-9. PubMed ID: 18565177
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial.
Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY
J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747
[TBL] [Abstract][Full Text] [Related]
18. Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): Results of a pilot trial.
Fine JD; Manes B; Frangoul H
J Am Acad Dermatol; 2015 Jul; 73(1):56-61. PubMed ID: 25956659
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial.
Lara-Corrales I; Parkin PC; Stephens D; Hamilton J; Koren G; Weinstein M; Sibbald RG; Pope E
J Am Acad Dermatol; 2012 Feb; 66(2):264-70. PubMed ID: 22153787
[TBL] [Abstract][Full Text] [Related]
20. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator.
Barker JN; Ashton RE; Marks R; Harris RI; Berth-Jones J
Br J Dermatol; 1999 Aug; 141(2):274-8. PubMed ID: 10468799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
